Sativex

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Sativex is an endocannabinoid system modulator principally containing Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). During… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND   Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report… (More)
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2011
Review
2011
People with multiple sclerosis may present with a wide range of disease symptoms during the evolution of the disease; among these… (More)
  • figure 1
  • table 2
  • table 1
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients. OBJECTIVE To compare… (More)
Is this relevant?
2010
2010
BACKGROUND Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE In this study we aimed to assess the… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Cannabinoids are known to have analgesic properties. We evaluated the effect of oro-mucosal sativex, (THC: CBD), an… (More)
  • figure 1
  • table 2
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA… (More)
Is this relevant?
Review
2006
Review
2006
Sativex is one of the first cannabis-based medicines to undergo conventional clinical development and to be approved as a… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The object of this study was to monitor the safety and efficacy of long-term use of an oromucosal cannabis-based medicine (CBM… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?